如何建立腹膜炎相关科研课题完整版.pptVIP

大肠杆菌和非大肠杆菌腹膜炎患者的人口学 及临床特征 Parameters Non-E. coli peritonitis (N = 271) E. coli peritonitis (N = 90) P value 年龄 (yr) 54 (41–67) 51.5 (38–64) 0.07 女性 [N, (%)] 121 (44.9%) 34 (37.8%) 0.22 BMI (kg/m2) 21.29 (19.28–23.10) 20.53 (18.79–23.59) 0.11 腹透时间 (mo) 16.4 (5.4–33.3) 13.29 (4.9–23.7) 0.11 糖尿病 [N, (%)] 67 (24.8%) 18 (20.0%) 0.21 合并症积分 4 (3–5) 3 (2–5) 0.08 eGFR (ml/min/1.73 m2) 7.18(5.67–9.03) 7.88(6.32–9.22) 0.13 BMI, body mass index; Index; eGFR, estimated glomerular filtration rate. 大肠杆菌分离株的耐药性及其影响因素 Antibiotics No. of resistant cases (%)a No. of cases with recent antibiotic use (%)b No. of cases with preceding peritonitis (%)c Ampicillin 57 (63.3%) 33 (57.9%) 36 (63.2%) * Ampicillin /Sulbactam 40 (44.4%) 22 (55%) 25 (62.5%) * Cefazolin 43 (47.8%) 25 (58.1%) 29 (67.4%)* Cefotetan 8 (9.1%) 6 (75.0%) 3 (37.5%) Ceftazidime 32 (35.6%) 19 (59.4%) 24 (75.0%)** Ceftriaxone 32 (35.6%) 18(56.3%) 23 (71.9%) Cefoperazone/Sulbactam 2 (3.6%) 1 (50%) 1 (50.0%) Cefepime 35 (38.9%) 19 (54.3%) 24 (68.6%)* Cefmetazole 1 (2.6%) 1 (100%) 0 Meropenem 1 (1.8%) 0 1 (100%) Ertapenem 1 (1.6%) 1 (100%) 0 Imipenem 2 ( 2.3%) 1 (50%) 1 (50%) Aztreonam 28 (31.1%) 17 (60.7%) 21 (75.0%)* Gentamicin 30 (33.3%) 18 (60%) 16 (53.3%) Amikacin 0 Levofloxacin 27 (30.0%) 19 (70.4%) 16 (59.3%) Ciprofloxacin 30 (33.3%) 22 (73.3%)* 15 (50.0%) Chemitrim 48 (53.3%) 34(70.8%)* 24 (50%) Furadantin 1 (1.2%) 1 (100%) 0 a: percentage of resistant strains among all E. coli isolates; b: percentage of resistant cases with recent antibiotic therapy; c: percentage of resistant cases with a history of peritonitis. Results are expressed as n (%). *: p 0.05, **: p 0.001. 大肠杆菌分离株对抗生素耐药性的变化 p 0.05 by poisson regression 头孢吡肟 头孢唑林 头孢他啶 氨苄青霉素 Feng XR, Yang X, et al. Perit Dial Int 2014 Feb 4 产ESBL大肠杆菌比例的变化趋势 year 产超广谱β-内酰胺酶（ESBL）大肠杆菌腹膜炎共有32例，ESBL发生率平均为35.5%。 腹膜炎病史增加产ESBL大肠杆菌的发生风险 OR: 5.286, 95% CI: 2.018 - 13.843; P = 0.001 无腹膜炎病史 有腹膜炎病史 Feng XR, Yang X, et al. Perit Dial Int 2014 Feb 4 腹透相关性